Trials / Completed
CompletedNCT01207115
A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee
A Global Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects With Osteoarthritis Pain of the Knee
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 322 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-652 | ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm |
| DRUG | Placebo | Placebo capsules - twice daily for 8 weeks |
| DRUG | Naproxen | Naproxen capsules - twice daily for 8 weeks |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2010-09-22
- Last updated
- 2013-01-07
Locations
38 sites across 5 countries: United States, Australia, Canada, Chile, Puerto Rico
Source: ClinicalTrials.gov record NCT01207115. Inclusion in this directory is not an endorsement.